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Abstract
Introduction: Postmenopausal women have higher risk of cardiovascular disease. One of the contributing factors could be reduced activity of anti-
atherogenic enzyme paraoxonase 1 (PON1). The aim of this study was to examine differences in the lipid status, paraoxonase and arylesterase PON1 
activities and PON1 phenotype in women with regular menstrual cycle and in postmenopausal women.
Materials and methods: The study included 51 women in reproductive age (25 in follicular and 26 in luteal phase of the menstrual cycle) and 23 
women in postmenopause. Lipid parameters in sera were determined using original reagents and according to manufacturer protocol. PON1 activity 
in serum was assessed by spectrophotometric method with substrates: paraoxon and phenylacetate. PON1 phenotype was determined by double 
substrate method.
Results: Compared to the women in follicular and luteal phase, postmenopausal women have significantly higher concentration of triglyceride [0.9 
(0.7-1.3), 0.7 (0.6-1.0) vs. 1.5 (0.9-1.7) mmol/L; P = 0.002], cholesterol [5.10 (4.78-6.10), 5.05 (4.70-5.40) vs. 6.30 (5.73-7.23) mmol/L; P < 0.001], LDL 
[3.00 (2.56-3.63), 3.00 (2.70-3.70) vs. 3.90 (3.23-4.50) mmol/L; P < 0.001], and apolipoprotein B [0.88 (0.75-1.00), 0.79 (0.68-1.00) vs. 1.07 (0.90-
1.24) mmol/L; P = 0.002]. PON1 basal [104 (66-260), 106 (63-250) vs. 93 (71-165) U/L; P = 0.847] and salt-stimulated paraoxonase activity [210 (131-
462), 211 (120-442) vs. 180 (139-296) U/L; P = 0.857] as well as arylesterase activity [74 (63-82), 70 (54-91) vs. 70 (60-81) kU/L; P = 0.906] and PON1 
phenotype (P = 0.810) were not different in the study groups.
Conclusion: There are no differences in PON1 activity and PON1 phenotype between women with regular menstrual cycle and postmenopausal 
women.
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A postmenopause, a physiological state in the 
woman life, is associated with the increased risk 
for cardiovascular disease (1-3). Risk factors include 
an atherogenic lipid profile, small increases of 
systolic and diastolic blood pressure and increased 
sympathetic tone. Furthermore, postmenopause 
is associated with central adiposity and increased 
insulin resistance (1,3). Among other, atherogenic 
lipid profile includes decreased or maintained lev-
el of high density lipoprotein (HDL) (1,3,4). Also, 
postmenopausal women show changes in the 
chemical composition of HDL, increased HDL oxid-
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ability and also decreased ability of HDL to prevent 
low density lipoprotein (LDL) oxidation (4).
One of the enzymes on HDL which possesses an-
tiatherogenic and antioxidant properties is paraox-
onase 1 (PON1) (5,6). PON1 is synthesized in the 
liver, secreted in the plasma where it is mainly as-
sociated with HDL (6,7). The N-terminal hydropho-
bic signal peptide of PON1 is structural require-
ment for bounding of the enzyme on the HDL (5). 
The association with HDL is necessary for obtain-
ing the optimal enzyme stability and activity (8,9). 
Enzyme hydrolyses different substrates by its or-
ganophosphatase, arylesterase and lactonase ac-
tivity (6,10-14). It was shown that PON1 has impor-
tant physiological role in lipid metabolism and 
prevention of atherosclerosis. It protects HDL 
against oxidation and preserves its function, pro-
tects LDL against oxidation and decreases lipid 
peroxide in atherosclerotic lesions (6). The differ-
ent non-genetic factors (like smoking, alcohol con-
sumption, diets and different physiological and 
pathological states) and genetic factors [polymor-
phism of paraoxonase 1 (pon1) gene] affect PON1 
activity which show large interindividual variabili-
ty (up to 40 times) (5,6,15-18). PON1 phenotype is 
influenced by genetic and non-genetic factors 
(5,15).
Zago and co-workers reported changes in concen-
tration, composition and function of HDL in post-
menopausal women (4) which could have the ef-
fect on the PON1 activity. We assume that reduced 
activity of antioxidant enzyme like PON1 could 
also contribute to the higher risk of cardiovascular 
events in postmenopausal women. So, we aimed 
to investigate difference in the lipid status, paraox-
onase and arylesterase PON1 activities and PON1 
phenotype between women with regular men-
strual cycle and postmenopausal women.
Materials and methods
Subjects
This case-control study was conducted in Depart-
ment of medical biochemistry and haematology, 
Faculty of Pharmacy and Biochemistry, University 
of Zagreb and Polyclinic Bonifarm, Zagreb. Sub-
jects were recruited during December 2013 in Pol-
yclinic Aviva, Zagreb and Department of Gynae-
cology and Obstetrics, Medical School University 
Hospital Sestre Milosrdnice, Zagreb, Croatia.
The study included 23 apparently healthy women 
with spontaneous natural menopause and with 
normal cervical smear. Also, 51 apparently healthy 
premenopausal women with regular menstrual 
cycle and normal cervical smear were included in 
the study. 25 of them were in the follicular phase 
of the cycle (blood was collected from 3rd-12th 
day of cycle) and 26 were in luteal phase of the cy-
cle (blood was collected from 19th day of cycle). 
All women were examined by general practitioner 
and gynaecologist. Health and menstrual status 
(pre- and postmenopausal) was defined by the 
questionnaire, and self-reported during interviews 
with the physicians. World Health Organization 
definition for postmenopausal was used, it consid-
er postmenopausal status as absence of menstrua-
tion for at least 12 months (19). Exclusion criteria 
were: cardiovascular, renal, liver or neoplastic dis-
ease, diabetes mellitus and diseases of reproduc-
tive organs, use of oral contraceptive levonorg-
estrel-releasing intrauterine system or hormone 
replacement therapy, pregnant women and wom-
en with surgical-evoked menopause.
The study was approved by the Ethic Committee 
of Medical School University Hospital Sestre Milos-
rdnice, Zagreb, Croatia and Polyclinic Aviva, Za-
greb, Croatia. All participants signed informed 
consent.
Samples
Samples were collected after 12 hour of fasting, 
into serum tubes with clot activator (Greiner Bio-
One, Kremsmünster, Austria). After 30 minutes of 
resting for spontaneous clotting, samples were 
centrifuged at 2000 x g for 10 minutes at room 
temperature and sera were stored at -20 °C until 
further analysis.
Methods
Concentrations of triglyceride, total cholesterol, 
HDL cholesterol, LDL cholesterol, apolipoprotein 
AI (apoAI) and apolipoprotein B (apoB) were deter-
mined on Cobas Integra 400 plus (Roche, Mannhe-
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im, Germany) with original reagents and according 
to manufacturer protocol (Roche, Mannheim, Ger-
many).
PON1 activity in serum was assessed by using two 
different substrates: paraoxon (PON1 paraoxonase 
activity) and phenylacetate (PON1 arylesterase ac-
tivity).
PON1 paraoxonase activity was measured in the 
absence and in the presence of NaCl (basal and 
salt-stimulated paraoxonase activity) on the BC-
AU680 analyzer (Beckman Coulter, Brea, CA, USA) 
at 37 °C, as described previously (20). Briefly, reac-
tion mixture contained 15 μL of serum and 300 μL 
of reagent [2.5 mmol/L paraoxon of ~ 90% purity 
(Sigma Aldrich Chemica GmbH, Steinheim, Germa-
ny) 2.2 mmol/L CaCl2 (Kemika, Zagreb, Croatia) in 
0.1 mol/L Tris-HCl buffer, pH 8.0 (Sigma Aldrich 
Chemica GmbH, Steinheim, Germany)]. For salt-
stimulated paraoxonase activity buffer contained 
1.0 mol/L NaCl. The release of p-nitrophenol was 
measured at 410/480 nm (ε = 17900 l/mol cm) and 
the PON1 enzyme activity was calculated. Accord-
ing to our data, intra-assay coefficients of variation 
(CV’s) were 1.42% and 1.75% for basal and NaCl 
stimulated PON1 activity, respectively. The quality 
of obtained results was monitoring by participat-
ing in interlaboratory comparisons.
Paraoxonase PON1 activity was presented as a ba-
sal (POX) and salt stimulated (POX1) paraoxonase 
activity and as activities standardized on the con-
centration of HDL (POX/HDL and POX1/HDL) and 
ApoA1 (POX/ApoA and POX1/ApoA).
PON1 arylesterase activity was determined by pre-
viously described method (20), which was modi-
fied for determination on microplate reader (1420 
Victor3, PerkinElmer, Waltham, MA, USA). Stock so-
lution of substrate [100 mmol/L phenylacetate, 
99% purity (Sigma Aldrich Chemica GmbH, Stein-
heim, Germany) in 40% methanol (Kemika, Zagreb, 
Croatia)] was diluted 5x while serum samples were 
diluted 100x with 0.1 mol/L Tris-HCl buffer, pH 8.0 
which contained 2 mmol/L CaCl2. Reaction mix-
ture for determination of arylesterase activity in 
serum samples (total volume 0.3 mL) contained 
0.24 mL buffer (0.1 mol/L Tris-HCl buffer, pH 8.0 
which contained 2 mmol/L CaCl2), 0.03 mL 20 
mmol/L phenylacetate and 0.03 mL of diluted se-
rum. Reaction mixture for determination of spon-
taneous substrate hydrolysis (total volume 0.3 mL) 
contained 0.27 mL buffer (0.1 mol/L Tris-HCl buffer, 
pH 8.0 which contained 2 mmol/L CaCl2) and 0.03 
mL 20 mmol/L phenylacetate. The release of phe-
nol was measured at room temperature continu-
ously (every 30 seconds) during 4 minutes at 260 
nm (ε = 1310 l/mol cm) on the microplate reader. 
Calculated PON1 arylesterase activities in sera 
samples were corrected for spontaneous substrate 
hydrolysis.
Arylesterase PON1 activity (ARE) was also stand-
ardized on the concentration of HDL (ARE/HDL) 
and ApoA1 (ARE/ApoA1).
PON1 phenotype was determined by double sub-
strate method (21). Briefly, phenotype is defined as 
the activity ratio of NaCl stimulated paraoxonase 
activity divided by arylesterase activity. Calcula-
tion was performed for each individual and was 
used for assigning subjects to one of the PON1 
phenotypes AA (homozygous low activity), AB 
(heterozygous intermediate activity) or BB (ho-
mozygous high activity). The cumulative distribu-
tion of individuals with respect to arylesterase ac-
tivity is unimodal and with respect to paraoxonase 
activity is bimodal. The cumulative distribution of 
the rate of paraoxonase to arylesterase activities is 
trimodal. This ratio divides the populations at the 
two antimodes (21). In our study two antimodes in 
group of women in follicular phase of menstrual 
cycle were 2.63 and 5.78 (AA phenotype activity 
ratio 2.63 and lower; BB phenotype activity ratio 
5.78 and higher, AB phenotype activity ratio high-
er from 2.63 and lower from 5.78). Two antimodes 
in group of women in lutheal phase of menstrual 
cycle were 3.97 and 8.83 (AA phenotype activity 
ratio 3.97 and lower; BB phenotype activity ratio 
8.83 and higher, AB phenotype activity ratio high-
er from 3.97 and lower from 8.83). Antimodes in 
group of postmenopausal women were 2.69 and 
7.53 (AA phenotype activity ratio 2.69 and lower; 
BB phenotype activity ratio 7.53 and higher, AB 
phenotype activity ratio higher from 2.69 and low-
er from 7.53).
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Statistical analysis
Statistical analysis was performed using SigmaStat 
for Windows, version 3.0 (2003. SPSS Inc, Erkrath, 
Germany). Data are presented as median (inter-
quartile range) or as counts (proportions). Age is 
presented as median and range (minimum and 
maximum). Due to the small study group we used 
non-parametric statistic. Quantitative data were 
tested using the Kruskal-Wallis Analysis of Variance 
on Ranks and Dunn’s method was used for Post 
hoc testing. Chi-square test was used for compari-
son of proportions. P values lower than 0.05 were 
considered statistically significant.
Results
Median age of postmenopausal women subgroup 
(N = 23) was 55 (45-69) years. Group of premeno-
pausal females (N = 51) were divided on two sub-
groups according to the menstrual cycle phase; 
follicular phase (N = 25) with median age of 36 (23-
49) years and luteal phase (N = 26) with median 
age of 36 (24-46) years.
Lipid parameters for the study groups are present-
ed in the Table 1. Compared to the both premeno-
pausal groups, postmenopausal women had sig-
nificantly higher concentration of total cholesterol, 
triglycerides, LDL cholesterol and ApoB. No differ-
ences in concentration of HDL cholesterol and 
ApoA1 were found between all groups. Post hoc 
testing showed significant difference in concentra-
tion of cholesterol, LDL cholesterol and ApoB be-
tween postmenopausal women and premenopau-
sal women in follicular and in luteal phase of the 
menstrual cycle. On the other hand, post hoc test 
showed that concentration of triglyceride is differ-
ent only between postmenopausal women and 
premenopausal women in the luteal phase of the 
cycle.
Table 2. shows paraoxonase and arylesterase PON1 
activity and this activities standardized on the con-
centration of HDL and apoA1 in the tested groups. 
There were no significant differences in the POX, 
POX1 and ARE and in the standardized activities of 
PON1 between premenopausal and postmeno-
pausal women. Table 3. shows the number and 
frequency of individuals having certain pheno-
type. Distribution of PON1 phenotypes was not 
different in the pre- and postmenopausal women.
Discussion
Our study was performed to investigate differenc-
es in the lipid profile, paraoxonase and aryleste-
rase PON1 activity and PON1 phenotype in pre-
menopausal and postmenopausal women. Our re-
sult show atherogenic lipid profile in postmeno-
pausal women, higher concentrations of triglycer-
ides, total cholesterol, LDL cholesterol and apoB. 
On the other hand paraoxonase and arylesterase 
Table 1. Lipid parameters in premenopausal and postmenopausal women.




(N = 23) P
Triglycerides (mmol/L) 0.9 (0.7-1.3) 0.7 (0.6-1.0) 1.5 (0.9-1.7) 0.002b
Total Cholesterol (mmol/L) 5.10 (4.78-6.10) 5.05 (4.70-5.40) 6.30 (5.73-7.23) <0.001a,b
HDL (mmol/L) 1.7 (1.4-2.0) 1.7 (1.5-1.9) 1.7 (1.4-2.0) 0.870
LDL (mmol/L) 3.00 (2.56-3.63) 3.00 (2.70-3.70) 3.90 (3.23-4.50) <0.001a,b
ApoA (g/L) 1.68 (1.48-1.94) 1.70 (1.58-1.81) 1.78 (1.60-1.97) 0.386
ApoB (g/L) 0.88 (0.75-1.00) 0.79 (0.68-1.00) 1.07 (0.90-1.24) 0.002a,b
Data are shown as the median (interquartile range); test by Kruskall-Wallis One Way Analysis of Variance on Ranks.
aPost hoc testing by Dunn’s method: significantly different values between premenopausal women in follicular phase of the 
menstrual cycle and postmenopausal women.
bPost hoc testing by Dunn’s method: significantly different values between premenopausal women in luteal phase of the menstrual 
cycle and postmenopausal women.
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Table 2. PON1 paraoxonase and arylesterase activities in premenopausal and postmenopausal women.




(N = 23) P
POX (U/L) 104 (66-260) 106 (63-250) 93 (71-165) 0.847
POX/HDL (U/mmol) 49 (38-153) 58 (42-131) 48 (36-94) 0.775
POX/apoAI (U/g) 50 (37-177) 60 (36-139) 51 (36-88) 0.528
POX1 (U/L) 210 (131-462) 211 (120-442) 180 (139-296) 0.857
POX1/HDL (U/mmol) 99 (72-272) 115 (81-237) 94 (69-169) 0.855
POX1/apoAI (U/g) 101 (74-315) 116 (69-248) 101 (71-156) 0.580
ARE (kU/L) 74 (63-82) 70 (54-91) 70 (60-81) 0.906
ARE/HDL (kU/L) 41 (36-51) 42 (35-50) 41 (32-49) 0.875
ARE/apoAI (kU/g) 41 (37-52) 44 (33-51) 37 (32-45) 0.346
Data are shown as the median (interquartile range); test by Kruskall-Wallis One Way Analysis of Variance on Ranks.
POX - Basal paraoxonase PON1 activity; POX1 - salt stimulated paraoxonase PON1 activity; ARE - arylesterase PON1 activity; POX/
HDL - basal paraoxonase PON1 activity standardized on the concentration of HDL; POX1/HDL - salt stimulated paraoxonase PON1 
activity standardized on the concentration of HDL; ARE/HDL - arylesterase PON1 activity standardized on the concentration of 
HDL; POX/apoA1- basal paraoxonase PON1 activity standardized on the concentration of apoA1; POX1/apoA1 - salt stimulated 
paraoxonase PON1 activity standardized on the concentration of apoA1; ARE/apoA1 - arylesterase PON1 activity standardized on 
the concentration of apoA1.
Table 3. PON1 phenotype in premenopausal and postmenopausal women.




(N = 23) P
AA 13 (0.52) 14 (0.54) 14 (0.61)
0.810AB 6 (0.24) 11 (0.42) 6 (0.26)
BB 6 (0.24) 1 (0.04) 3 (0.13)
Data are shown as absolute counts (proportions) of individuals having a certain phenotype; tested by Chi-square test. Due to the 
small number of samples we tested the significant differences between the phenotype AA and phenotype AB+BB in the group of 
women in the follicular phase, luteal phase and postmenopause.
Phenotype AA (homozygous low activity), AB (heterozygous intermediate activity) or BB (homozygous high activity).
PON1 activities as well as PON1 phenotype were 
similar in pre- and postmenopausal women.
Menopause is the physiological phase in the wom-
en’s life which is the result of the changes in their 
hormonal status (2). It was shown that higher car-
diovascular risk in postmenopausal women is con-
sequence of estrogen deficiency and ageing (2). 
Estrogen had indirect protective effects on lipid 
and glycaemic metabolism; furthermore it has di-
rect effect on vessel function (2). Postmenopause 
is associated with pro-atherogenic lipid profile, 
central adiposity, increased diastolic pressure and 
increased insulin resistance (1). Pro-atherogenic li-
pid profile is characterized in general with higher 
concentration of total cholesterol, LDL cholesterol, 
triglyceride and lipoprotein (a) (Lpa) (1,3). Further-
more, HDL cholesterol is maintained or decreased 
in postmenopausal women (4).
In our study, we compared the lipid profile of the 
healthy premenopausal (follicular and lutheal 
phase) and postmenopausal women. As it was ex-
pected the postmenopausal women have pro-
atherogenic lipid profile; higher concentration of 
total and LDL cholesterol and apoB, which is in ac-
cordance with previously published papers (4,22). 
Furthermore, we found higher concentration of 
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triglycerides in postmenopausal women com-
pared to the premenopausal women. Interestingly, 
only women in luteal phase of the cycle show sig-
nificant differences. This could be result of the dif-
ferences in the hormone status in these two phas-
es of the menstrual cycle and this finding must be 
confirmed in further studies which would include 
large number of subjects. Other authors also re-
ported significantly higher triglyceride concentra-
tion in postmenopausal women (4,22). Concentra-
tion of the HDL cholesterol and apoAI was similar 
in three examined group. The higher concentra-
tion of LDL cholesterol and unchanged concentra-
tion of HDL cholesterol could be risk factor for cor-
onary heart disease. The results of lipid profile in 
postmenopausal women are not consistent. For 
example, Zago and co-workers reported higher 
concentration of triglycerides, total and LDL cho-
lesterol and apoB, lower concentration of HDL and 
unchanged concentration of apoAI in postmeno-
pausal women (4). Mascarenhas-Melo et al. showed 
significantly higher concentration of LDL, lower 
concentration of HDL and unchanged concentra-
tion of total cholesterol and triglyceride in post-
menopausal women (23). On the other hand, 
Wakatsuki et al. did not find significant differences 
in the concentration of triglyceride, HDL cholester-
ol and ApoA1 between pre- and postmenopausal 
women and women with surgically caused meno-
pause. They also reported significantly higher con-
centration of total and LDL cholesterol and ApoB 
in the examined groups (24). Interestingly, one pa-
per did not find any significant differences in the 
lipid profile (cholesterol, triglycerides, LDL) be-
tween healthy pre- and postmenopausal women 
(25). The discrepancy in the results could be caused 
by differences in the study design, different eth-
nicity and lifestyles habits.
Furthermore, in this paper we determined the en-
zyme activity and phenotype of PON1 enzyme. It 
is well know that PON1 have antiatherogenic prop-
erties. It protects HDL and LDL from oxidation and 
destroys biologically active oxidized lipids on lipo-
proteins and arterial cells (6,26,27). The association 
of PON1 with HDL is important for serum enzyme 
activity. HDL stimulates secretion and stabilizes 
the secreted enzyme (9). Apo AI is not necessary 
for binding of PON1 on HDL but is important for 
enzyme stability and activity (5,8,9). PON1 is not 
associated with all types of HDL partials. Less than 
10% of total HDL reacts with anti-PON1 antibodies 
(9). Changes in HDL concentration, HDL composi-
tion and in distribution of HDL subfraction could 
lead to the change in PON1 activity. Zago and co-
authors showed that postmenopausal women 
have changed HDL chemical composition (4). HDL 
from postmenopausal women has higher content 
of triglycerides and lower concentration of choles-
terol compared to the premenopausal women (4). 
Only few papers examined the PON1 activity in 
postmenopausal women and paraoxon was usu-
ally used as the substrate. The paraoxonase activi-
ty of PON1 gives the information of the hydrolytic 
activity of the enzyme toward substrate paraoxon. 
Capacity of PON1 to protect LDL from oxidation is 
reversed to its paraoxon activity so the measure-
ment of PON1 paraoxonase activity gives very lim-
ited information (28). On the other hand, aryleste-
rase activity could be used for the estimation of 
PON1 concentration in serum (5,29). In this study, 
we determined both paraoxonase and aryleste-
rase activity in all examined group, and did not de-
tect significant differences in either of PON1 activi-
ties. Furthermore, we standardized paraoxonase 
and arylesterase activities of PON1 to the concen-
tration of HDL and apoA1. Standardized activity 
was also similar in all three groups examined as 
well as distribution of PON1 phenotype. Results re-
garding PON1 activity, which are reported in the 
literature, are also inconsistent. Zago reported that 
pre- and postmenopausal women had similar ba-
sal and salt stimulated paraoxonase PON1 activity 
as well as arylesterase PON1 activity (4). The ab-
sence of differences in paraoxonase PON1 activity 
was also reported in two papers (23,25). However, 
Topçuoglu and co-workers reported significantly 
lower paraoxonase PON1 activity in postmeno-
pausal women (22). It is well know that different 
non-genetic and genetic factors effect PON1 ac-
tivity (6,15-18). Discrepancies in the results ob-
tained could be consequence of different geno-
type distribution of polymorphisms in promoter 
or coding region of the pon1 gene which influence 
concentration, or activity of the enzyme. Further-
more different lifestyle habits could also explain 
different results.
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In this paper we did not show significant differ-
ence in the PON1 enzyme activities in postmeno-
pausal women, as compared to the women in fol-
licular and luteal phase of the menstrual cycle. In 
contrast to most of the authors we used two sub-
strates for determination of the PON1 activity and 
we also standardized these activities to concentra-
tion of HDL and apoA1. We confirmed findings of 
other authors that postmenopausal women have 
pro-atherogenic lipid profile. However, concentra-
tion of HDL was not changed in postmenopausal 
women. The results demonstrated that postmeno-
pausal women had a disturbance in the lipid pro-
file and increased risk of atherogenesis. However, 
the results did not establish a connection between 
PON1 activity and risk of atherosclerosis. The limi-
tation of our study was small number of studied 
subjects, but other authors have also used group 
of 50 or less study subjects (4,22,23,25). In order to 
obtain more reliable results further studies must 
include larger number of subjects. Further studies 
are needed to examine PON1 antioxidant ability in 
preventing oxidation of LDL and HDL in postmen-
opausal women.
In conclusion, the results of our study showed that 
there are no differences in PON1 activity and PON1 
phenotype between women with regular men-
strual cycle and postmenopausal women.
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